EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Deep PSA response and extended time‐to‐nadir as robust predictors of survival in Asian patients with de novo metastatic hormone‐sensitive prostate cancer receiving upfront intensified treatment

Chris H-M Wong, Ivan C-H Ko, David K-W Leung, Brian Siu, Cheuk-K K Cheng, Yung-Y J Lim, Hiu T Mok, Chun-F B Kwok, Cheuk Y Tang, Steven C-H Leung iD, Peter K-F Chiu, Jeremy Y-C Teoh und 1 weitere

The Prostate · 2025

DOI: 10.1002/pros.24797 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Chris H-M Wong und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, SH Ho Urology Centre, The Chinese University of Hong Kong, HKSAR, Hong Kong, China. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In de novo metastatic hormone‐sensitive prostate cancer (mHSPC) treated with upfront intensification using androgen receptor signaling inhibitor or chemotherapy (Docetaxel), achieving a PSA nadir less than 0.2 ng/mL, indicative of superior survival in trials, may often be unattainable in real‐world settings. We explored the predictive value of the degree of PSA decline and time to PSA nadir (TTPN) on oncological outcomes.

Methods

A prospectively maintained database of consecutive prostate cancer cases in Hong Kong was accessed. Patients diagnosed with de novo mHSPC from 2016 to 2022 and treated with upfront intensification were included in this analysis. Landmark analysis on PSA kinetics at 6‐months following treatment intensification was performed. They were classified based on 1) TTPN (≥6 months vs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic NeoplasmsHumansMaleAgedMiddle AgedDocetaxelHong KongProspective StudiesAsian PeopleTreatment OutcomeAged, 80 and overNeoplasm MetastasisAndrogen Receptor Antagonists

Stichwörter der Autor:innen

Asian patientsPSA kineticsandrogen receptor signaling inhibitordocetaxelmetastatic hormone‐sensitive prostate cancerupfront intensified treatment

Substanzen

Prostate-Specific AntigenDocetaxelAndrogen Receptor Antagonists

Autor:innen und Institutionen

  • Department of Surgery, SH Ho Urology Centre, The Chinese University of Hong Kong, HKSAR, Hong Kong, China.
  • Department of Urology, Medical University of Vienna, Vienna, Austria.
  • Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong.

ORCID-Profile: Steven C-H Leung

Zitieren

APA

Wong, C. H., Ko, I. C., Leung, D. K., Siu, B., Cheng, C. K., Lim, Y. J., Mok, H. T., Kwok, C. B., Tang, C. Y., Leung, S. C., Chiu, P. K., Teoh, J. Y., & Ng, C. F. (2025). Deep PSA response and extended time‐to‐nadir as robust predictors of survival in Asian patients with de novo metastatic hormone‐sensitive prostate cancer receiving upfront intensified treatment. The Prostate. https://doi.org/10.1002/pros.24797

Vancouver

Wong CH, Ko IC, Leung DK, Siu B, Cheng CK, Lim YJ, et al. Deep PSA response and extended time‐to‐nadir as robust predictors of survival in Asian patients with de novo metastatic hormone‐sensitive prostate cancer receiving upfront intensified treatment. The Prostate. 2025. doi:10.1002/pros.24797

BibTeX
@article{Wong2025,
  author = {Wong, Chris H-M and Ko, Ivan C-H and Leung, David K-W and Siu, Brian and Cheng, Cheuk-K K and Lim, Yung-Y J and Mok, Hiu T and Kwok, Chun-F B and Tang, Cheuk Y and Leung, Steven C-H and Chiu, Peter K-F and Teoh, Jeremy Y-C and Ng, Chi F},
  title = {Deep PSA response and extended time‐to‐nadir as robust predictors of survival in Asian patients with de novo metastatic hormone‐sensitive prostate cancer receiving upfront intensified treatment},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.24797}
}
Kostenlos starten →